API5

Across TCGA pan-cancer cohorts, API5 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated API5 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher API5 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated API5 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

HNSC, PDAC, and LUAD are the cancer types where API5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	All	0.751	0.955	.002	70	view →
PDAC	DFS	Tertile	IV	0.752	0.199	.024	4	view →
LUAD	DFS	Median	III,IV	0.432	0.925	.047	3	view →
CCRCC	DFS	Tertile	II,III,IV	0.781	0.522	.049	1	view →
LSCC	OS	Quartile	All	0.951	0.750	.018	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

API5–HNSC (OS)

Open the HNSC breakdown →